Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL11241682 | 1.00 | ALDH1A1 (0.61) | ALDH1A1HSD17B10EPHX1HIF1ASLC18A3 | |
| Biphenyl SCHEMBL4942278 | 0.96 | ALDH1A1 (0.57) | ALDH1A1HSD17B10EPHX1HIF1ASLC18A3 | |
| Biphenyl SCHEMBL12497681 | 0.96 | ALDH1A1 (0.57) | ALDH1A1HSD17B10EPHX1HIF1ASLC18A3 | |
| Carbimide SCHEMBL28002161 | 0.96 | ALDH1A1 (0.67) | ALDH1A1HSD17B10 | |
| Biphenyl SCHEMBL8071601 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 | |
| SCHEMBL61560 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 | |
| Biphenyl SCHEMBL15309189 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 | |
| Biphenyl SCHEMBL4048778 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 | |
| SCHEMBL5201533 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 | |
| SCHEMBL11035602 | 0.86 | ALDH1A1 (0.53) | ALDH1A1EPHX1HIF1ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389165-A1 | Diamine Compound, Polyimide Precursor and Polyimide Film Using the Same, and Use Thereof | SK IE TECHNOLOGY CO., LTD. (KR) | 2022-12-08 | — | — | US | disclosed |
| CN-106433390-A | Curing agent for epoxy anticorrosion primer and preparation method thereof | 中海油常州涂料化工研究院有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2343973-B1 | Prodrugs of Sitagliptin | CADILA PHARMACEUTICALS LTD (IN) | 2016-02-17 | — | — | EP | disclosed |
| US-9029567-B2 | Hypoglycemic compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-9024039-B2 | Heterocycles and derivatives thereof and methods of manufacture and therapeutic use | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2769978-A1 | saxagliptin derivatives | Cadila Pharmaceuticals Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140045771-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | Cadila Corporated Campus (IN) | 2014-02-13 | — | — | US | disclosed |
| US-8563517-B2 | Dipeptidyl peptidase IV (DP-IV) compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| EP-2555617-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | Cadila Pharmaceuticals Limited (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| EP-0651739-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS. | BRITISH BIOTECH PHARM (GB) | 1995-05-10 | — | — | EP | disclosed |
| EP-0651738-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995009841-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
| EP-0634998-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS. | BRITISH BIO TECHNOLOGY (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994024140-A1 | HYDROXAMIC ACID DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994021625-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994002446-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1994002447-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993020047-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389165-A1 | Diamine Compound, Polyimide Precursor and Polyimide Film Using the Same, and Use Thereof | PUF60, PARG, DDT | ALDH1A1 1920/4885HSD17B10 3954/4885EPHX1 3995/4885 |
| US-20140045771-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | DPP4, DPP3, DPP7 | ALDH1A1 708/4885HSD17B10 1173/4885EPHX1 1311/4885 |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | GLP1R, GPR119, IAPP | ALDH1A1 818/4885HSD17B10 408/4885EPHX1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.